VidhiAagaz
International Journal ofLaw Management & Humanities
ISSN 2581-5369 · Open access
International Journal ofLaw Management & Humanities
Open accessArticlesVol. 4 No. II (2021)pp. 73–79

Patent Linkage in FTAs and Indian Position

NP
Dr. Nandita S. PatilAssistant Professor, Department of P.G. Studies in Law, Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, India.Google Scholar
3,483views1,379downloads
Published 7 March 2021 · pp. 73–79 · Vol. 4 No. II (2021)
Abstract

The system of patent linkage links the drugs marketing approval to the status of patent. TRIPS Agreement which sets minimum standards for IPR for the WTO member countries does not provide for patent linkage. This is a TRIPS plus provision which is included in the FTAs and is also found in the domestic legislation of countries such as USA, China, Singapore, Chile, Bahrain, Morocco, Australia. Doha Declaration on the TRIPS Agreement and Public Health affirms that the TRIPS agreement can and should be interpreted and implemented to protect public health and promote access to affordable medicines. There are two separate Acts in India, one Drugs and Cosmetic Act 1940 for granting marketing approval and other is Patent Act 1970 for granting patent. On the issue of Article 39.3 of the TRIPS Agreement Satwant Reddy Committee considers no need for a separate legislation for protecting test data but suggested inclusion of ‘data exclusivity’ like mechanism in DCA. India does not provide for patent linkage system and the same is maintained by the Courts in India when the MNCs tried to create patent linkage by filing suits.

Keywords
Patent linkageTRIPSFTAsData exclusivityIndia

How to cite

Dr. Nandita S. Patil, Patent Linkage in FTAs and Indian Position, 4 Int'l J.L. Mgmt. & Human. 73 (2021).

Cite this article

Dr. Nandita S. Patil, Patent Linkage in FTAs and Indian Position, 4 Int'l J.L. Mgmt. & Human. 73 (2021).
Chat with us